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1.  Introduction
Lung cancer is clinically divided into small cell 
lung cancer (SCLC) and non-small cell lung cancer 
(NSCLC). SCLC is neuroendocrine neoplasm with an 
aggressive biological behavior and generally a marked 
initial response to polychemotherapy. NSCLC is a 
heterogeneous group of neoplasm with various dif-
ferentiation characteristics. NSCLC represents 75−
80% of all primary lung cancers which make up the 
bulk of lung cancer cases [1,2].
At presentation, only about 30% of NSCLC are 
localized and surgery is usually the optimal treat-
ment choice for the disease [3]. However, even in 
cases of successful surgeries, recurrences are ob-
served in most patients as the disease takes its 
course. For inoperable patients with locally ad-
vanced disease or metastatic disease at the time 
of diagnosis, no curative treatments are available. 
Overall, the prognosis of lung cancer is poor, with a 
less than 15% of 5-year survival rate [4]. Generally 
accepted prognostic factors, such as TNM staging, 
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performance status, and histological types do not 
serve as a reliable prediction source for disease 
progression in an individual patient [3−5].
In Korea, ginseng (Panax ginseng C.A. Meyer) 
has long been used as a general tonic or as an 
adaptogen to promote longevity and enhance bod-
ily functions. It has also been claimed to be effec-
tive in stress reduction, fatigue, oxidants, diabetes 
mellitus and cancer [6]. Panax meaning “cure all” 
in Greek, it is widely accepted that wild ginseng is 
more effective than cultivated ginseng for anti-
cancer and chemoprevention purposes [7,8].
Pharmacopuncture therapy (PT) is a therapeutic 
method derived from combining herbal medicine and 
acupuncture therapy [9]. Mountain Ginseng Phar-
macopuncture (MGP) is a type of PT used in cancer 
treatments and other progressive disorders such as 
amyotropic lateral sclerosis [10]. Our team has con-
ducted numerous researches during the past sev-
eral years on MGP including anecdotal tales, case 
reports, toxicity studies, cell culture experiments, 
animal experiments, mechanism studies and some 
of case reports related with cancer patients [11−
19]. However, these data of dosage, treatment pe-
riod and cancer types are not sufficient to support 
the anticancer effect of MGP. Therefore this clini-
cal study was conducted to observe the efficacy of 
MGP on NSCLC patients treated by different types 
of delivery methods.
2.  Methods
2.1.  Eligibility
A total of 6 NSCLC patients were observed from 
August 2007 to December 2009. Informed consents 
were obtained from all patients. The places of set-
tings were made in two hospitals in Daejeon and 
Wonju, Korea. Eligibility is shown below:
(1) Histologically or radiologically diagnosed NSCLC;
(2) Eastern Cooperative Oncology Group (ECOG) ≤ 3;
(3) Measurable malignant disease using the inter-
national standard of Response Evaluation Criteria 
in Solid Tumors (RECIST); complete/partial re-
sponse (CR/PR), progression/stable disease 
(PD/SD);
(4) Completion of anticancer drugs and/or radia-
tion treatment 3 weeks prior to participation;
(5) Recovery from all side effects of anticancer 
drugs and/or radiation treatment;
(6) Proper bone marrow function (peripheral abso-
lute granulocyte count > 150 × 109/L, platelet 
count > 100 × 109/L);
(7) Proper liver function (bilirubin ≤ 1.5 mg/dL, 
serum glutamic pyruvic transaminase or serum 
glutamic oxaloacetic transaminase < 3 × normal) 
and kidney function (creatinine ≤ 1.5 mg/dL).
2.2.  Treatment
Each patient received either MGP 20 mL/day of in-
travenous infusion or MGP 10 mL/day of acupoint 
(LU1) injection. There were 4 weeks (28 days) in one 
treatment cycle. MGP was prepared as the method 
of previous studies [18,19].
2.3.  Tumor measurement for response rate
Computed tomography (CT) scan was performed at 
the beginning of the treatment to measure the ini-
tial tumor size, then again at every 2 treatment 
cycles (8 weeks). Response rate was measured by 
the RECIST standard; complete response (CR), partial 
response (PR), stable disease (SD) and progressive 
disease (PD) was used. Compared to initial tumor 
size, a 30% or greater decrease in size was confirmed 
as PR, a 20% or greater increase was confirmed as 
PD; if neither PR nor PD was confirmed, then it is 
an SD.
3.  Results
3.1.  Patients characteristics
Of the 6 patients that were followed, there were 
five male (83.3%) and one female (16.7%) patients. 
They all had NSCLC, two squamous cell carcinoma 
(33.3%), two adenocarcinoma (33.3%) and others 
(33.3%). Three patients were in stage IV (50.0%) and 
two patients were in stages III (33.3%) (Table 1).
3.2.  Case reports
Case 1 was a 64-year-old male patient diagnosed 
with NSCLC adenocarcinoma stage IV. He was ini-
tially diagnosed at a hospital in October 2006 and 
had gone through resection of right upper lobe and 
right lower lobe along with adjuvant chemother-
apy. After chemotherapy, another cancer was found 
in left upper lobe (Figure 1A). LU1 acupoint injec-
tion of MGP 10 mL/day was administered from July 
to October 2008. The treatment outcome was un-
successful and the tumors had progressed accord-
ing to the chest CT (Figure 1B). Then the patient 
had changed to intravenous infusion of MGP 20 mL/
day from October 2008 to February 2009. During the 
treatment, cancer markers in blood analysis showed 
normal range, and tumor growth has stopped for 
9 weeks (Figure 1C). However, even with continu-
ous MGP intravenous infusion, increasing masses 
were observed in February 2009 (Figure 1D).
Case 2 was a 60-year-old male patient diagnosed 
with NSCLC squamous cell carcinoma stage IV with 
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Figure 1 Chest computed tomography (CT) taken during treatment. (A) Chest CT on August 11th, 2008. (B) Chest CT 
on October 6th, 2008. (C) Chest CT on December 9th, 2008. (D) Chest CT on February 9th, 2009. The tumors in (B) 
were increased than the tumors in (A). The tumors in (C) showed no interval changes compared with the tumors in 
(B). The tumors in (D) were markedly increased than the tumors in (C).
Table 1 Characteristics of patients
Case no. 1 2 3 4 5 6
Gender
 Male      
 Female   
NSCLC tumor history   
 Adenocarcinoma
 Squamous cell carcinoma      
 Others     
Tumor stage IV IV IV NA IIIA IIIB
Pretreatment
 Chemotherapy  
 Operation  
Method of MGP treatment
 Acupoint injection     
 Intravenous injection      
Age (yr) Median (range) 66.5 (60−78)
MGP = mountain ginseng pharmacopuncture; NSCLC = non-small cell lung carcinoma; NA = not available.
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metastasis to right anterior thoracic wall (Figure 2A). 
He was initially diagnosed at a hospital in December 
2004 and had gone through multiple surgeries due 
to uncontrolled metastasis to right and left upper 
lobes (December 2004, April 2006, and August 2006). 
Nonetheless, the tumor has progressed and the pa-
tient received extensive chemotherapy from October 
2007 to May 2008. We administered intravenous in-
fusion of MGP 20 mL/day from November 2008 to 
February 2009. During treatment, tumor growth 
has shown stable condition for 4 weeks (Figure 2B) 
but chest CT taken on February 2009 has revealed 
slight progression of the disease (Figure 2C).
Case 3 was a 62-year-old female patient diag-
nosed with NSCLC squamous cell carcinoma stage 
IV (T4N2M1). Her primary tumor was located in 
right middle lobe with multiple metastasis to re-
gional lymph nodes and bones (Figure 3A). She was 
initially diagnosed at a hospital in July 2008. She had 
refused all conventional therapy. We administered 
acupoint injection of MGP 10 mL/day from August 
to October 2008, but tumor was markedly increased 
accompanied by pleural effusion according to the 
chest CT taken in September 2009 (Figure 3B).
Case 4 was a 70-year-old male patient diagnosed 
with NSCLC. He was initially diagnosed at a hospi-
tal in July 2008 with masses found in RML (Figure 
4A). He had breathing difficulties with weight loss. 
He refused all conventional therapies due to his 
old age and wished to be treated with oriental 
medicine. We administered acupoint injection of 
MGP 10 mL/day from July to August 2008, but 
tumor size has slightly increased according to the 
chest CT taken in August 2008 (Figure 4B).
Case 5 was a 65-year-old male patient diagnosed 
with NSCLC squamous cell carcinoma stage IIIa with 
masses located in left upper lobe (Figure 5A). He was 
initially diagnosed at a cancer center in November 
2007 and had refused all conventional therapies. 
We administered intravenous infusion of MGP 20 mL/
day from November 2007 to May 2008. The tumor 
growth has shown stable condition for 20 weeks 
(Figure 5B). However it was not continued the in-
travenous infusion delivery with his refusal and MGP 
treatment via acupoint injection 10 mL/day was ap-
plied from June to September 2008. During treat-
ment, tumor size has slightly increased according 
to the chest CT taken in September 2008 (Figure 5C). 
While the patient was resting at home pneumonia 
was found with lung cancer (Figure 5D).
Case 6 was a 78-year-old male patient diag-
nosed with NSCLC squamous cell carcinoma stage 
IIIb. His primary tumor was located in right middle 
lobe (Figure 6A) with accompanying symptoms of 
dyspnea, hemoptysis, fever and weight loss. He was 
initially diagnosed at a hospital on August 2008 and 
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Figure 2 Chest computed tomography (CT) taken dur-
ing treatment. (A) Chest CT taken on November 11th, 
2008. (B) Chest CT on December 18th, 2008. (C) Chest CT 
on February 19th, 2009. (B) had no significant difference in 
mass size compared with (A). (C) showed slightly increased 
extent of cancer compared with (B).
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had refused all conventional therapies due to his old 
age. We administered intravenous infusion of MGP 
20 mL/day from August 2008 to December 2009. 
During treatment, all cancer related symptoms and 
the tumor growth has shown stable condition for 
16 months (Figure 6B). Patient was discharged later 
on as he refused all further treatments.
4. Discussion
In terms of incidence and mortality, lung cancer is 
one of the leading cancers in the world. The inci-
dence of lung cancer is rapidly growing in Korea as 
well, now accounting for 12% of all cancers, with 
relatively low survival rate [20−22].
Treatment for lung cancer depends on their his-
tological subtypes and staging of the disease. The 
strongest predictor of the treatment guidelines and 
prognosis for lung cancer is the American Joint 
Commission on Cancer (AJCC)’s staging system for 
NSCLC [23]. The TNM staging system is based on the 
pathological size of the primary tumor (T), regional 
lymph nodes involvement (N) and presence or ab-
sence of distant metastasis (M). Approximately 45% 
of lung cancers are limited to chest, where surgical 
resection is possible with postsurgery survival rate 
ranging from 55 to 85% [24,25]. Unfortunately, most 
NSCLC patients are diagnosed at locally advanced 
stages (stage IIIb) or metastatic stages (stage IV) 
and the survival time without treatment is poor 
(< 6 months) [26−28]. Chemotherapy, such as gem-
citabine, is the standard treatment for advanced 
NSCLC, but most NSCLC patients undergoing che-
motherapy experience common side effects of these 
chemotherapeutic regiments including nausea/
vomiting, nephrotoxicity, and neurotoxicity [29].
Today, cancer patients receiving conventional 
medical care also seek other treatments such as 
complementary and alternative medicine (CAM) [30]. 
CAM is more prevalent in Asia due to the popularity 
of traditional medicine. Oriental medicine is used by 
many countries on various diseases, and currently 
there are many clinical trials and researches being 
A B
Figure 3   Chest computed tomography (CT) taken during treatment. (A) Chest CT taken on July 22nd, 2008. (B) Chest CT 
on September 3rd, 2008. (B) showed markedly increased right pleural effusion and both lung metastatic nodules than (A).
A B
Figure 4   Chest computed tomography (CT) taken during treatment. (A) Chest CT on July 14th, 2008. (B) Chest CT on 
August 22nd, 2008. Both images showed known lung cancer mass about 3 cm in size in the right middle lobe. (B) showed 
slightly increased mass size than (A).
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done in the field of traditional medical oncology with 
the advancement of CAM worldwide.
Mountain Ginseng (Ginseng; Panax ginseng 
C.A. Meyer), a Korean traditional medicinal herb 
has been used clinically in Korea and also in other 
C D
A B
Figure 5   Chest computed tomography (CT) taken during treatment. (A) Chest CT on November 29th, 2007. (B) Chest 
CT on May 8th, 2008. (C) Chest CT on September 23rd, 2008. (D) Chest CT on November 27th, 2008. (A) and (B) were 
taken before and after the intravenous infusion of MGP and the tumors had shown no interval change. (B) and (C) were 
taken before and after the acupoint injections and the tumor had increased. (D) showed lung mass with pneumonia.
A B
Figure 6 Positron emission tomography (PET) and chest computed tomography (CT) taken before and after the intra-
venous infusion of mountain Ginseng pharmacopunture and the tumors had shown no interval change. (A) PET and CT 
in August 2008. (B) Chest CT followed in October 2009.
Asian countries for thousands of years [6]. In can-
cer care, most studies claim that the pharmacolog-
ical effects of ginseng are attributed to its bioactive 
constituents such as ginsenosides, saponins, phy-
tosterols, peptides, polysaccharides, fatty acids, 
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improvements or remained stable, whereas most 
patients who received MGP via intravenous infusion 
showed stable disease for 2−16 cycles.
Although this study is an investigator initiated 
observational trial (I.I.T.) of a case series, it still 
holds significance as MGP treatments are already 
clinically used for cancer management in Korean 
oriental medicine. Though the amount used for in-
travenous infusion (20 mL/day) compared to intra 
acupoint injection (10 mL/day) could act as a bias, 
intravenous delivery method was linked to better 
prognosis of patients according to our observation. 
This research suggests the future application of 
intravenous delivery method could play an impor-
tant factor in conducting pharmacopuncture treat-
ment in Korea, where intravenous infusion uses 
are limited unlike China where Traditional Chinese 
Medicine frequently incorporates the intravenous 
delivery method for herbal injections.
In conclusion, confirmed efficacies of MGP for 
NSCLC cases are not yet clear, but the results of 
our study demonstrated the delivery of MGP via in-
travenous infusion with better efficacy than the 
acupoint injection. Further studies of MGP are 
needed to build more concrete evidence.
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Table 2  Summary of patient cases
Case no. Date of diagnosis
 Prior given Administration No. of 
Results (RECIST)
  conventional therapy on mode of MGP cycles*
1 10/2006 Operation Acupoint   2 Disease progression (PD)
  Chemothrapy  injection
   Intravenous  4 No interval changed (SD)
    infusion
2 12/2004 Operation Intravenous  4 No interval changed (SD)
  Chemothrapy  infusion
3 7/2008 None Acupoint  2 Marked increased Right
    injection   pleural effusion and both 
      lung metastatic nodules (PD)
4 7/2008 None Acupoint  1 Slightly increased mass
    injection   size (SD)
5 11/2007 None Acupoint  2 Increased mass size (PD)
    injection  
   Intravenous  5 No interval changed (SD)
    infusion  
6 7/2008 None Intravenous 16 No interval changed during
    infusion   14 cycles (SD)
*One cycle consists of 28 days of being treated with MGP daily. MGP = mountain ginseng pharmacopuncture; RECIST = 
Response Evaluation Criteria in Solid Tomors; PD = progression disease; SD = stable disease.
polyacetylenes, vitamins, and minerals. There are 
many types of flavonoid compounds such as quer-
cetin, hesperidin and anthocyacanidins. Several 
flavonoids scavenge reactive oxygen species. Other 
flavonoids suppress the pro-inflammatory and 
growth promoting gene mediated by nuclear fac-
tor kappa B (NF-κB). Flavonoids also interfere with 
signal transduction pathways, reducing tumor ini-
tiation and promotion [31].
In previous studies, MGP has demonstrated its 
anti-tumor effects and safety [11,12]. Inhibitory 
effect against hepatic metastasis using Colon 26-L5 
carcinoma cells injected through hepatic portal 
vein was shown [8]. Induction of apoptosis on A549 
human lung cell cancer lines was also observed 
[13]. Clinical studies using MGP on multiple meta-
static hepatocellular carcinoma cases [15] and on 
other various cancers over stage III have been per-
formed recently [19]. These researches show the 
potential of MGP as an effective measure in main-
taining tumor size and enhancing the quality of 
life of cancer patients.
This study was done to observe the effectiveness 
of MGP on NSCLC patients depending on the delivery 
method. The patients were treated over one cycle 
of MGP from August 2007 to December 2009 at the 
hospitals in Daejeon and Wonju, Korea. Six patients 
were observed during and after the completion of 
treatment.
As seen in Table 2, patients who received MGP 
via acupoint injection at LU1 have not shown any 
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